News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Actelion Ltd. Swings to Profit, Key Drug Tracleer Disappoints
April 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, April 22 (Reuters) - Swiss biotech company Actelion Ltd swung to a first-quarter net profit of 48 million Swiss francs ($47.43 million), but results were hit by the weak dollar and sales of key drug Tracleer disappointed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Business
Opinion: Investing in Research and Welcoming Global Talent Strengthens America
June 4, 2025
·
4 min read
·
Dr. Chris Otiko
Podcast
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
June 4, 2025
·
2 min read
·
Heather McKenzie
Tariffs
Rare Disease, Cell and Gene Therapy at Risk From Trump Tariffs, Industry Says
June 3, 2025
·
4 min read
·
Annalee Armstrong
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
June 2, 2025
·
2 min read
·
Dan Samorodnitsky
